[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350250-105":59,"doc-detail-350250-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","defining-the-tumor-microenvironment-of-non-small-cell-lung-cancer","Defining the tumor microenvironment of non-small cell lung cancer","","Lung cancer is the leading cause of cancer-related death worldwide, and immunotherapy has substantially changed treatment for advanced non-small-cell lung cancer (NSCLC), producing durable responses for some patients. However, most patients fail to achieve sustained benefit and develop resistance, driving progression. Limited success is linked to tumor heterogeneity and the complex tumor microenvironment (TME). The review summarizes NSCLC, details key TME features, and surveys advanced technologies such as spatial profiling, plus emerging therapies and predictive biomarker testing toward precision medicine.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/defining-the-tumor-microenvironment-of-non-small-cell-lung-cancer/350250/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/defining-the-tumor-microenvironment-of-non-small-cell-lung-cancer/350250.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does immunotherapy benefit only a subset of NSCLC patients?","Question",{"text":112,"@type":113},"Only some patients achieve sustained benefit, while most develop resistance that leads to progression. The review links this limited success to tumor heterogeneity and the intricate composition of the tumor microenvironment (TME).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the key features of the tumor microenvironment (TME) emphasized in the review?",{"text":117,"@type":113},"The review focuses on dissecting TME heterogeneity by identifying drivers of cancer progression and immunotherapy resistance. It frames TME as a dynamic ecosystem affecting treatment response.",{"name":119,"@type":110,"acceptedAnswer":120},"Which technologies are highlighted for studying the TME?",{"text":121,"@type":113},"The review highlights advanced technologies, especially spatial profiling of tissues, to analyze the dynamicity of the tumor ecosystem. It connects these tools to more effective individualized treatment strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350250,1791377228,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Immunology & Cell Biology 2026; 104: 499–518 [www.wileyonlinelibrary.com/journal/icb](www.wileyonlinelibrary.com/journal/icb)  \nREVIEW OPEN  \nDeﬁning the tumor microenvironment of non-small cell lung cancer  \nKidane Siele Embaye 1, Tony Blick 1, Vahid Yaghoubi Naei 1,2, Ken O’Byrne3, Brett G. M. Hughes4,5 & Arutha Kulasinghe 1,6   \n1 Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia  \n2 School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, Australia  \n3 The Princess Alexandra Hospital, Brisbane, QLD, Australia  \n4 The Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia  \n5 Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, QLD, Australia  \n6 Queensland Spatial Biology Centre, Wesley Research Institute, The Wesley Hospital, Brisbane, QLD, Australia  \nKeywords  \nimmunotherapy, lung cancer, NSCLC, tumor microenvironment  \nCorrespondence  \nArutha Kulasinghe, Frazer Institute, Health, Medicine and Behavioural Sciences, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia.  \nE-mail: [arutha.kulasinghe@uq.edu.au](arutha.kulasinghe@uq.edu.au)  \nReceived 9 July 2025;  \nRevised 23 March 2026; Accepted 27 March 2026  \ndoi: 10.1111/imcb.70114  \nImmunology & Cell Biology 2026; 104: 499–518  \nAbstract  \nLung cancer is the most frequent cause of cancer-related mortality globally. In recent years, the treatment landscape for advanced-stage non-small-cell lung cancer (NSCLC) has been transformed by the advent of immunotherapy, which has yielded unprecedented and durable clinical responses for some patients. This shift has powered a signiﬁcant expansion of novel immunotherapeutic strategies in oncology over the past few decades, heralding a new direction in the management of NSCLC. Despite these advances, only a fraction of patients acquire sustained beneﬁt from immunotherapy, while the majority often develop resistance, resulting in disease progression leading to death. Several factors may contribute to this limited success, notably tumor heterogeneity and the intricate composition of the tumor microenvironment (TME) . As a result, it is imperative to fully dissect the heterogeneity of the TME by identifying the principal drivers of cancer progression and immunotherapy resistance. This understanding is crucial for optimizing individualized treatment approaches. Here, we provide a summary of NSCLC, discuss the cardinal features of the TME and review advanced technologies such as spatial proﬁling of tissues, which are useful in dissecting the dynamicity of the tumor ecosystem. In addition, we highlight the recent developments and future perspectives of immunotherapy and other emerging therapeutics, as well as the role of predictive biomarker testing to ensure tailored therapy and tackle drug resistance, on the pathway to precision medicine.  \nINTRODUCTION  \nNon-small cell lung cancer  \nBased on the 2022 global cancer report, lung cancer remains the leading cause of cancer related mortality worldwide, with approximately 2.5 million new cases andover 1 .8 million deaths.1 Non-small cell lung cancer (NSCLC) makes up around 85% of all lung cancer cases and is further categorized into three main morphological subtypes: adenocarcinoma (50%), squamous cell  \ncarcinoma (35%) and large cell carcinoma (15%) .2,3 Small cell lung cancer (SCLC) is the second histological variant, which displays a more aggressive behavior with rapid proliferation and poor survival outcomes.4 Patients with advanced disease of these cancers originating from the mucosa of the bronchus or the gland-forming structures have an unfavorable prognosis with less than one-year median overall survival.5  \nSurgical excision of tumors, together with chemoradiotherapy, has traditionally been considered the backbone of cancer treatment. Starting from the early  \nTumour microenvirnoment of NSC","cbCaipd0YmfuK0qY","https://ap.wps.com/l/cbCaipd0YmfuK0qY","pdf",1268033,"English","# Abstract\n# Introduction\n## Non-small cell lung cancer\n## Immune checkpoint inhibitors and limitations\n# Tumor microenvironment and resistance","[{\"question\":\"Why does immunotherapy benefit only a subset of NSCLC patients?\",\"answer\":\"Only some patients achieve sustained benefit, while most develop resistance that leads to progression. The review links this limited success to tumor heterogeneity and the intricate composition of the tumor microenvironment (TME).\"},{\"question\":\"What are the key features of the tumor microenvironment (TME) emphasized in the review?\",\"answer\":\"The review focuses on dissecting TME heterogeneity by identifying drivers of cancer progression and immunotherapy resistance. It frames TME as a dynamic ecosystem affecting treatment response.\"},{\"question\":\"Which technologies are highlighted for studying the TME?\",\"answer\":\"The review highlights advanced technologies, especially spatial profiling of tissues, to analyze the dynamicity of the tumor ecosystem. It connects these tools to more effective individualized treatment strategies.\"}]","Defining the tumor microenvironment of non-small cell lung cancer | PDF",1790088034,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7db0d9c9232ab683df9ea4ea00bfd96.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3207139ffaebf05d50edd975053127b5.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d45991b84d6620b158a508cfa35cb17.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc2a060c42d453237592ee59122b2e6d.webp",980,1287]